- Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res 2003;109 (Suppl 1): S9–S15.
- Eriksson UG, Bredberg U, Gislen K, Johansson LC, Frison L, Ahnoff M, Gustafsson D. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 2003;59: 35–43.
- Food and Drug Administration. Cardiovascular and Renal Drugs Advisory Committee; notice of meeting. Federal Register 2004(August 10); 69 (153): 48509–48510. Available at http://www.fda.gov/OHRMS/DOCKETS/98fr/04-18166.htm; accessed October 13, 2004.
- Wahlander K, Lapidus L, Olasson C, Thuresson A, Eriksson U, Larson G, Eriksson H. Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb Res 2002;107: 93–99.
- Gustafsson D, Nystrom J, Carlsson S, Bredberg U, Eriksson U, Gyzander E, Elg M, Antonsson T, Hoffmann K, Ungell A, Sorensen H, Nagard S, Abrahamsson A, Bylund R. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001;101: 171–181.
- Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, Peters GR, Roth AW, McElhattan J, Colwell CW Jr; EXULT A Study Group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003;349: 1703–1712.
- Hutchison TA, Shahan DR, eds. DRUGDEX® System. Greenwood Village, CO: MICROMEDEX, Inc., edition expires 9/2004.
- Eriksson BI, Bergqvist D, Kalebo P, Dahl OE, Lindbratt S, Bylock A, Frison L, Eriksson UG, Welin L, Gustafsson D; Melagatran for Thrombin Inhibition in Orthopaedic Surgery. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002;360: 1441–1447.
- Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, Eskilson C, Nylander I, Frison L, Ogren M; METHRO III Study Group. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003;89: 288–296.
- Colwell CW Jr, Berkowitz SD, Davidson BL, Lotke PA, Ginsberg JS, Lieberman JR, Neubauer J, McElhattan JL, Peters GR, Francis CW. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost 2003;1: 2119–2130.
- Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H; THRIVE III investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349: 1713–1721.
- Petersen P, Grind M, Adler J; SPORTIF II investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol 2003;41: 1445–1451.
- Olsson SB; executive steering committee on behalf of the SPORTIF III investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362: 1691–1698.
- Halperin JL; executive steering committee, SPORTIF III and V study investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003;146: 431–438.
- Early trial results from SPORTIF V. Presented at the Scientific Sessions of the American Heart Association, November 9–12, 2003. First Report 2003. Available at http://www.princetoncme.com/pdf/FirstReport_SportifV.pdf; accessed October 29, 2004.
- AstraZeneca. Press releases. Available at http://www.astrazeneca.com/archivelist/2003.aspx; accessed October 13, 2004.
- FDAAdvisoryCommittee.com. AstraZeneca Exanta liver toxicity outweighs benefit, cmte. says. Available at http://www.fdaadvisorycommittee.com/FDC/AdvisoryCommittee/Committees/Cardiovascular+and+Renal+Drugs/091004_Exanta/091004_ExantaR.htm; accessed October 13, 2004.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 18, 2005 - Issue 1